C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
08 août 2023 07h00 HE
|
C4 Therapeutics, Inc.
Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC; U.S. IND Cleared Ongoing Phase 1/2 Clinical Trials of...
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 juil. 2023 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., July 17, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
05 juil. 2023 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD)...
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
20 juin 2023 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC
30 mai 2023 07h00 HE
|
C4 Therapeutics, Inc.
C4 Therapeutics to Receive a $10 Million Upfront Payment, a $25 Million Equity Investment and is Eligible to Receive up to $357 Million for Development and Commercial Milestones Plus Royalties on Net...
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
04 mai 2023 07h00 HE
|
C4 Therapeutics, Inc.
Preclinical Data Presented at AACR Demonstrated CFT1946 is a Potent and Mutant-Selective BRAF V600 BiDAC™ Degrader; Phase 1/2 Clinical Trial Enrolling Patients Phase 1 Dose Escalation Data from the...
C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
19 avr. 2023 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
23 févr. 2023 07h00 HE
|
C4 Therapeutics, Inc.
Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Expected in 2H 2023 Phase 1/2 Clinical Trial...
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
08 févr. 2023 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors
30 janv. 2023 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science...